Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Richards, Frances M ^a   Tape, Christopher J ^a   Jodrell, Duncan I ^a   Murphy, Gillian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; D1(A12) ANTIBODY; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID LEVEL; BIOLUMINESCENCE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADAM PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84863845567     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040597     Document Type: Article

References (61)

1. Saftig P, Reiss K, (2011) The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 90: 527-535.
2. Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, et al. (2011) ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol 163: 324-332.
3. Narita D, Seclaman E, Ursoniu S, Anghel A, (2012) Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. Acta Histochem 114: 131-139.
4. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, et al. (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131: 41-48.
5. Ringel J, Jesnowski R, Moniaux N, Luttges J, Choudhury A, et al. (2006) Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res 66: 9045-9053.
6. Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, et al. (2005) Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207: 156-163.
7. Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W, et al. (2011) Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol 178: 1792-1804.
8. Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, et al. (2009) Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci 100: 654-662.
9. Zhou BB, Peyton M, He B, Liu C, Girard L, et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10: 39-50.
10. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, et al. (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 16: 2022-2035.
11. Kornfeld JW, Meder S, Wohlberg M, Friedrich RE, Rau T, et al. (2011) Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer 104: 138-145.
12. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, et al. (2007) The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 5: 1246-1253.
13. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, et al. (2009) ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8: 1045-1054.
14. Santiago-Josefat B, Esselens C, Bech-Serra JJ, Arribas J, (2007) Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J Biol Chem 282: 8325-8331.
15. Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, et al. (2011) Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res 71: 1071-1080.
16. Zheng X, Jiang F, Katakowski M, Lu Y, Chopp M, (2011) ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog.
17. Szalad A, Katakowski M, Zheng X, Jiang F, Chopp M, (2009) Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia. J Exp Clin Cancer Res 28: 129.
18. Lin P, Sun X, Feng T, Zou H, Jiang Y, et al. (2011) ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem.
19. Franovic A, Robert I, Smith K, Kurban G, Pause A, et al. (2006) Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res 66: 8083-8090.
20. Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, et al. (2010) ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res 70: 5368-5378.
21. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, et al. (2010) Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun 2: 229.
22. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, et al. (2010) Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 106: 932-940.
23. Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, et al. (2008) VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 103: 916-918.
24. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, et al. (2010) Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 16: 3378-3389.
25. Gijsen M, King P, Perera T, Parker PJ, Harris AL, et al. (2010) HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 8: e1000563.
26. Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, et al. (2007) Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13: 1892-1902.
27. Zucker S, Cao J, Chen WT, (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19: 6642-6650.
28. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, et al. (2008) Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 68: 7083-7089.
29. Moss ML, Sklair-Tavron L, Nudelman R, (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4: 300-309.
30. Qian M, Bai SA, Brogdon B, Wu JT, Liu RQ, et al. (2007) Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans. Drug Metab Dispos 35: 1916-1925.
31. Thabet MM, Huizinga TW, (2006) Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 7: 1014-1019.
32. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, et al. (2004) Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22: 4683-4690.
33. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, et al. (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23: 842-849.
34. Heath EI, O'Reilly S, Humphrey R, Sundaresan P, Donehower RC, et al. (2001) Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48: 269-274.
35. Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, et al. (2006) A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 102: 300-308.
36. Tape CJ, Willems SH, Dombernowsky SL, Stanley PL, Fogarasi M, et al. (2011) Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A 108: 5578-5583.
37. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, et al. (2007) The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67: 585-592.
38. Hassan MI, Kassim SK, Saeda L, Laban M, Khalifa A, (1999) Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue. Anticancer Res 19: 5657-5662.
39. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR, (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194-2206.
40. Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, et al. (2005) Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23: 5950-5959.
41. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, et al. (2011) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res.
42. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, et al. (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19: 1340-1346.
43. Lee MH, Knauper V, Becherer JD, Murphy G, (2001) Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem Biophys Res Commun 280: 945-950.
44. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, et al. (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45: 4970-4979.
45. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
46. Ghetie J, Ward ES, Vitetta ES, (2004) Pharmacokinetics of antibodies and immunotoxins in mice and humans. In: H.L FWDaM, editors. pp. 475-498 editor. Handbook of anticancer pharmacokinetics and pharmacodynamics: Humana Press.
47. Ober RJ, Radu CG, Ghetie V, Ward ES, (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551-1559.
48. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, et al. (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26: 690-696.
49. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, et al. (2011) Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 71: 2250-2259.
50. Kennel SJ, Falcioni R, Wesley JW, (1991) Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts. Cancer Res 51: 1529-1536.
51. Mezyk-Kopec R, Bzowska M, Stalinska K, Chelmicki T, Podkalicki M, et al. (2009) Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts. Cytokine 46: 309-315.
52. Armanious H, Gelebart P, Anand M, Belch A, Lai R, (2011) Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFalpha/NFkappaB pathway. Blood 117: 6237-6246.
53. Hikita A, Tanaka N, Yamane S, Ikeda Y, Furukawa H, et al. (2009) Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha. Biochem Cell Biol 87: 581-593.
54. Zheng Y, Saftig P, Hartmann D, Blobel C, (2004) Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 279: 42898-42906.
55. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, et al. (2005) Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123: 291-304.
56. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281: 13964-13971.
57. Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, et al. (2011) Inhibition of the inflammatory cytokine TNF-alpha increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Mol Ther 19: 490-499.
58. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, et al. (1990) A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63: 251-258.
59. Georgopoulos S, Plows D, Kollias G, (1996) Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46: 86-97.
60. Grell M, Douni E, Wajant H, Lohden M, Clauss M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
61. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426.